<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277705</url>
  </required_header>
  <id_info>
    <org_study_id>711866/003</org_study_id>
    <nct_id>NCT01277705</nct_id>
  </id_info>
  <brief_title>Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®</brief_title>
  <official_title>Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa &amp; IPV Vaccines Administered Separately &amp; Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents &amp; Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will assess the immunogenicity and reactogenicity of the candidate GSK
      Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis-
      inactivated poliovirus vaccine when administered to healthy subjects aged ≥ 15 years in
      Germany and ≥ 18 years in France compared to Boostrix™ and inactivated poliovirus vaccine
      administered separately, and with Revaxis®
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>One month after vaccination (Month 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>One month after vaccination (Month 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to some component of the study vaccines</measure>
    <time_frame>At Day 10 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local and general symptoms</measure>
    <time_frame>within 15 (Day 0-14) days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms</measure>
    <time_frame>within 30 days (Day 0-29) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>Throughout the entire study (from Day 0 to Day 30)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">806</enrollment>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Acellular Pertussis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine</intervention_name>
    <description>Intramuscular, single</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix™</intervention_name>
    <description>Intramuscular, single dose</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' IPV vaccine</intervention_name>
    <description>Intramuscular, single dose</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Revaxis®</intervention_name>
    <description>Intramuscular, single dose</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female subjects aged 15 years and over (Germany), or 18 years and over
             (France) at the time of the vaccination.

          -  Written informed consent obtained.

          -  Free of obvious health problems Having received primary vaccination with diphtheria
             and tetanus vaccines to the best of his/her knowledge.

          -  Female subjects must not be pregnant or lactating.

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the administration of the study vaccine dose, or
             planned use during the study period.

          -  History of previous or intercurrent diphtheria or tetanus, pertussis or polio disease
             in the last 10 years.

          -  French subjects: history of diphtheria or tetanus, pertussis or polio vaccination in
             the last 10 years.

          -  German subjects: history of diphtheria or tetanus, pertussis or polio vaccination in
             the last 5 years, except those subjects participating in the tetanus antibody kinetic
             subgroup.

          -  German subjects participating in the tetanus antibody kinetic subgroup: history of
             diphtheria or tetanus, pertussis or polio vaccination in the last 10 years.

          -  Administration or planned administration of a vaccine not foreseen by the study
             protocol during the period starting 30 days before the administration of the study
             vaccine dose and ending 30 days after study vaccination.

          -  Chronic administration or planned administration of immuno-suppressants or other
             immune-modifying drugs within six months or 5 half-lives (whichever is the longer) of
             vaccination.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the study vaccination or planned administration during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition,

          -  History of seizures or progressive neurological disease.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  The following adverse experiences associated with diphtheria-tetanus-pertussis
             vaccination constitute absolute contraindications to further administration of
             diphtheria-tetanus-pertussis vaccine; if any of these adverse experiences occurred
             following previous vaccinations, the subject should not be included:

        Absolute contraindications:

          -  Hypersensitivity reaction due to the vaccine.

          -  Encephalopathy

        Precautions:

          -  Fever &gt;= 40.0°C within 48 hours of vaccination not due to another identifiable cause.

          -  Collapse or shock-like state within 48 hours of vaccination.

          -  Persistent, inconsolable crying lasting &gt;= 3 hours occurring within 48 hours of
             vaccination.

          -  Seizures with or without fever occurring within 3 days of vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine. 2011 Aug 11;29(35):5932-9. doi: 10.1016/j.vaccine.2011.06.049. Epub 2011 Jun 28.</citation>
    <PMID>21718738</PMID>
  </reference>
  <results_reference>
    <citation>Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine. 2005 May 25;23(28):3657-67.</citation>
    <PMID>15882526</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolter J et al. Boostrix polio: A new combined vaccine to fulfill emerging needs for pertussis vaccination of older age-groups. Abstract presented at the ESPID, Tampere, Finland, 26-28 May 2004.</citation>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Booster vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>711866/003</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711866/003</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711866/003</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711866/003</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711866/003</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711866/003</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

